Jci_page_head_homepage_01 Jci_page_head_homepage_02
Yukihiro Takemura, Noriyuki Ouchi, Rei Shibata, Tamar Aprahamian, Michael T. Kirber, Ross S. Summer, Shinji Kihara, Kenneth Walsh
Published in Volume 117, Issue 2
J Clin Invest. 2007; 117(2):375–386 doi:10.1172/JCI29709
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 3
Systemic delivery of adiponectin decreases remnant apoptotic levels and inflammation in lpr strains of mice.

(A) Adenovirus-mediated overexpression of adiponectin decreases apoptotic cells in lymph nodes of B6.lpr mice at the age of 12 weeks and MRL.lpr mice at the age of 20 weeks. Lymph node sections were stained with TUNEL and quantified by microscopy (n = 6–8). (B) ANA titers and anti-dsDNA antibody titer in the serum of B6.lpr or MRL.lpr mice at 14 days after Ad-APN or Ad–β-gal administration. **P < 0.01 versus Ad–β-gal. (C) Adiponectin overexpression influences renal function and morphology. Photographs show representative glomeruli of MRL.lpr mice treated with Ad–β-gal or Ad-APN 14 days prior to sacrifice. Glomerular tuft volume of control is 3.1 × 105 ± 0.1 × 105 μm3. Scale bar: 50 μm. Urinary albumin is reported as μg protein/d. *P < 0.05 versus Ad–β-gal (n = 8).